BioLineRx Ltd. (TLV:BLRX)

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of ILS 46.99 million. The enterprise value is 1.19 million.

Market Cap	46.99M
Enterprise Value	1.19M

Important Dates

The last earnings date was Monday, November 24, 2025.

Earnings Date	Nov 24, 2025
Ex-Dividend Date	n/a

Share Statistics

BioLineRx has 2.61 billion shares outstanding. The number of shares has increased by 86.44% in one year.

Current Share Class	2.61B
Shares Outstanding	2.61B
Shares Change (YoY)	+86.44%
Shares Change (QoQ)	+10.02%
Owned by Insiders (%)	0.16%
Owned by Institutions (%)	3.51%
Float	2.50B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.11
PB Ratio	0.73
P/TBV Ratio	1.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.12
EV / Sales	0.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.03

Financial Position

The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.58.

Current Ratio	2.09
Quick Ratio	1.90
Debt / Equity	0.58
Debt / EBITDA	n/a
Debt / FCF	-0.84
Interest Coverage	-1.85

Financial Efficiency

Return on equity (ROE) is -21.24% and return on invested capital (ROIC) is -18.24%.

Return on Equity (ROE)	-21.24%
Return on Assets (ROA)	-13.60%
Return on Invested Capital (ROIC)	-18.24%
Return on Capital Employed (ROCE)	-38.53%
Revenue Per Employee	1.51M
Profits Per Employee	-352,041
Employee Count	28
Asset Turnover	0.28
Inventory Turnover	2.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -77.78% in the last 52 weeks. The beta is 0.58, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y)	0.58
52-Week Price Change	-77.78%
50-Day Moving Average	2.03
200-Day Moving Average	2.15
Relative Strength Index (RSI)	42.03
Average Volume (20 Days)	5,983,692

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioLineRx had revenue of ILS 42.17 million and -9.86 million in losses. Loss per share was -0.00.

Revenue	42.17M
Gross Profit	21.38M
Operating Income	-33.35M
Pretax Income	-9.86M
Net Income	-9.86M
EBITDA	-27.72M
EBIT	-33.35M
Loss Per Share	-0.00

Balance Sheet

The company has 83.48 million in cash and 37.67 million in debt, giving a net cash position of 45.81 million or 0.02 per share.

Cash & Cash Equivalents	83.48M
Total Debt	37.67M
Net Cash	45.81M
Net Cash Per Share	0.02
Equity (Book Value)	64.68M
Book Value Per Share	0.02
Working Capital	49.19M

Cash Flow

In the last 12 months, operating cash flow was -44.65 million and capital expenditures 19,867, giving a free cash flow of -44.63 million.

Operating Cash Flow	-44.65M
Capital Expenditures	19,867
Free Cash Flow	-44.63M
FCF Per Share	-0.02

Margins

Gross margin is 50.69%, with operating and profit margins of -79.08% and -23.38%.

Gross Margin	50.69%
Operating Margin	-79.08%
Pretax Margin	-23.38%
Profit Margin	-23.38%
EBITDA Margin	-65.73%
EBIT Margin	-79.08%
FCF Margin	n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-86.44%
Shareholder Yield	-86.44%
Earnings Yield	-20.98%
FCF Yield	-94.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.

Last Split Date	Jun 7, 2015
Split Type	Reverse
Split Ratio	0.1

Scores

BioLineRx has an Altman Z-Score of -13.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.52
Piotroski F-Score	2